

## Estimating all cancers incidence with the MIAMOD model: a new method to include multiple tumors

Leonardo Ventura<sup>1</sup>, Guido Miccinesi<sup>1</sup>, Claudio Sacchetti<sup>1</sup>,  
and Roberta De Angelis<sup>2</sup>

<sup>1</sup>ISPO Cancer Research and Prevention Institute, Florence; <sup>2</sup>Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy

---

### ABSTRACT

---

**Aims and background.** The MIAMOD method has been widely applied to derive regional and national cancer burden estimates. The method is based on a back-calculation approach using cancer-specific mortality and relative survival to derive expected incident and prevalent cases. Multiple tumors occurring in the same site for the same person (for example colon-colon) can be estimated just once. This has little effect on cancer-specific estimates, whereas it limits all cancers-combined estimates, where only cancer *cases*, rather than cancer *diagnoses*, can be accounted for by the method. The aim of this article is to present a specific strategy of application of the MIAMOD method to all cancers sites, which better approximates an estimate of 'cancer diagnoses'.

**Methods.** The strategy consists of breaking down the estimation process in separate applications to the most frequent cancer sites and to a 'remainder-site', given by all malignant sites except the previous ones. The separate estimates are then summed up to derive the overall quantities for all cancers combined. Cancer-specific mortality in the years 1985-2004 in the Tuscany cancer registry area (about 1,200,000 inhabitants) and relative survival data in the same area and periods (end of follow-up, 31 December 2006) were used to produce the estimates, which were then tested using observed incidence data in the same area and period.

**Results.** The standard application of the MIAMOD method underestimates all cancer incidence for both sexes. The mean relative difference between observed and expected incident cases is -14.8% for males and -17.2% for females. With the alternative method, the same mean relative difference drops to -8.2% for males and -6.1% for females.

**Conclusions.** The study provides a strategy to reduce a structural limit of the MIAMOD method in estimating the total burden of cancer disease.

---

**Key words:** age-period-cohort model, cancer registry, incidence, MIAMOD, multiple tumors.

Source of support (grants, equipment, drugs): none.

Conflict of interest: none.

Correspondence to: Leonardo Ventura, via delle Oblate 2, 50141 Florence, Italy.  
Tel +39-055-7972502;  
fax +39-055-7972535;  
email l.ventura@ispo.toscana.it

Received September 8, 2011;  
accepted January 26, 2012.